Adaptive Biotechnologies Corporation

5 days ago · globenewswire.com

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or measurable) residual disease (MRD) assessment as an important tool in myeloma care.

6 days ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

1 month ago · geekwire.com

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode

2 months ago · seekingalpha.com

Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2 months ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.

2 months ago · marketbeat.com

Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering.

2 months ago · globenewswire.com

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.